TY - JOUR
T1 - An accelerated shift in the use of remote systems in epilepsy due to the COVID-19 pandemic
AU - Kuchenbuch, Mathieu
AU - d'Onofrio, Gianluca
AU - Wirrell, Elaine
AU - Jiang, Yuwu
AU - Dupont, Sophie
AU - Grinspan, Zachary M.
AU - Auvin, Stephane
AU - Wilmshurst, Jo M.
AU - Arzimanoglou, Alexis
AU - Cross, J. Helen
AU - Specchio, Nicola
AU - Nabbout, Rima
N1 - Funding Information:
The authors wish to thank the practitioners who participated in this study and the networks without whom this study could not have been carried out, namely the International League Against Epilepsy, the International Child Neurology Association, the French League Against Epilepsy, the French Society of Pediatric Neurology, and the ERN EpiCARE network. Rima Nabbout was supported by State funding from the Agence Nationale de la Recherche under “Investissements d'avenir” program (ANR-10-IAHU-01) and the “Fondation Bettencourt Schueller”.
Funding Information:
The authors wish to thank the practitioners who participated in this study and the networks without whom this study could not have been carried out, namely the International League Against Epilepsy, the International Child Neurology Association, the French League Against Epilepsy, the French Society of Pediatric Neurology, and the ERN EpiCARE network. Rima Nabbout was supported by State funding from the Agence Nationale de la Recherche under ?Investissements d'avenir? program (ANR-10-IAHU-01) and the ?Fondation Bettencourt Schueller?. This research was supported by the Agence Nationale de la Recherche under ?Investissements d'avenir? program (ANR-10-IAHU-01) and the ?Fondation Bettencourt Schueller?, Paris, France.
Funding Information:
This research was supported by the Agence Nationale de la Recherche under “Investissements d'avenir” program ( ANR-10-IAHU-01 ) and the “ Fondation Bettencourt Schueller ”, Paris, France.
Funding Information:
M. Kuchenbuch, G D'Onofrio, Y. Jiang, ZM Grinspan, J Wilmshurst and R Nabbout have any conflict of interest to disclose. S Dupont has received honoria from EISAI, UCB, GW, Novartis, Advicenne and Shire. E Wirrell has acted as an investigator for GW Pharma and Zogenix and has received consulting fees from Biocodex and Biomarin. S Auvin has served as consultant or received honoraria for lectures from Arvelle therapeutics, Biocodex, Eisai, GW Pharma, Novartis, Nutricia, UCB Pharma, Zogenyx. He has been investigator for clinical trials for Advicenne Pharma, Eisai, UCB Pharma and Zogenyx. A Arzimanoglou has served as consultant, received honoraria for lectures from Arvelle therapeutics, Eisai, GW Pharma, UCB Pharma and Zogenix. On behalf of his Instiitution he has been investigator for clinical trials sponsored by Eisai, GW, UCB Pharma and Zogenix. JH Cross has acted as an investigator for studies with GW Pharma, Zogenix, Vitaflo and Marinius. She has been a speaker and on advisory boards for GW Pharma, Zogenix, and Nutricia; all remuneration has been paid to her department. Her research is supported by the National Institute of Health Research (NIHR) Biomedical Research Centre at Great Ormond Street Hospital, NIHR, EPSRC, GOSH Charity, ERUK, the Waterloo Foundation. N Specchio has acted as an investigator for studies with Zogenix, Marinus, Biomarin, and Livanova, and has received consulting fees from Zogenix, Biomarin, Arvelle, Livanova.
Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2020/11
Y1 - 2020/11
N2 - Purpose: The purpose of the study was to describe epileptologists' opinion on the increased use of remote systems implemented during the COVID-19 pandemic across clinics, education, and scientific meetings activities. Methods: Between April and May 2020, we conducted a cross-sectional, electronic survey on remote systems use before and during the COVID-19 pandemic through the European reference center for rare and complex epilepsies (EpiCARE) network, the International and the French Leagues Against Epilepsy, and the International and the French Child Neurology Associations. After descriptive statistical analysis, we compared the results of France, China, and Italy. Results: One hundred and seventy-two respondents from 35 countries completed the survey. Prior to the COVID-19 pandemic, 63.4% had experienced remote systems for clinical care. During the pandemic, the use of remote clinics, either institutional or personal, significantly increased (p < 10−4). Eighty-three percent used remote systems with video, either institutional (75%) or personal (25%). During the pandemic, 84.6% of respondents involved in academic activities transformed their courses to online teaching. From February to July 2020, few scientific meetings relevant to epileptologists and routinely attended was adapted to virtual meeting (median: 1 [25th–75th percentile: 0–2]). Responders were quite satisfied with remote systems in all three activity domains. Interestingly, before the COVID-19 pandemic, remote systems were significantly more frequently used in China for clinical activity compared with France or Italy. This difference became less marked during the pandemic. Conclusion: The COVID-19 pandemic has dramatically altered how academic epileptologists carry out their core missions of clinical care, medical education, and scientific discovery and dissemination. Close attention to the impact of these changes is merited.
AB - Purpose: The purpose of the study was to describe epileptologists' opinion on the increased use of remote systems implemented during the COVID-19 pandemic across clinics, education, and scientific meetings activities. Methods: Between April and May 2020, we conducted a cross-sectional, electronic survey on remote systems use before and during the COVID-19 pandemic through the European reference center for rare and complex epilepsies (EpiCARE) network, the International and the French Leagues Against Epilepsy, and the International and the French Child Neurology Associations. After descriptive statistical analysis, we compared the results of France, China, and Italy. Results: One hundred and seventy-two respondents from 35 countries completed the survey. Prior to the COVID-19 pandemic, 63.4% had experienced remote systems for clinical care. During the pandemic, the use of remote clinics, either institutional or personal, significantly increased (p < 10−4). Eighty-three percent used remote systems with video, either institutional (75%) or personal (25%). During the pandemic, 84.6% of respondents involved in academic activities transformed their courses to online teaching. From February to July 2020, few scientific meetings relevant to epileptologists and routinely attended was adapted to virtual meeting (median: 1 [25th–75th percentile: 0–2]). Responders were quite satisfied with remote systems in all three activity domains. Interestingly, before the COVID-19 pandemic, remote systems were significantly more frequently used in China for clinical activity compared with France or Italy. This difference became less marked during the pandemic. Conclusion: The COVID-19 pandemic has dramatically altered how academic epileptologists carry out their core missions of clinical care, medical education, and scientific discovery and dissemination. Close attention to the impact of these changes is merited.
KW - E-health
KW - E-learning
KW - Remote work system
KW - Teleconsultations
KW - Telemedicine
KW - Virtual meeting
UR - http://www.scopus.com/inward/record.url?scp=85090013684&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85090013684&partnerID=8YFLogxK
U2 - 10.1016/j.yebeh.2020.107376
DO - 10.1016/j.yebeh.2020.107376
M3 - Article
C2 - 32882627
AN - SCOPUS:85090013684
SN - 1525-5050
VL - 112
JO - Epilepsy and Behavior
JF - Epilepsy and Behavior
M1 - 107376
ER -